{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:26Z","timestamp":1788306566376,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/2\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In October 2014, MenB-FHbp (Trumenba, Pfizer) became the first meningococcal group B vaccine licensed in the United States. It is approved for use in individuals aged 10\u201325 years. Our objective was to evaluate the safety of MenB-FHbp postlicensure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Vaccine Adverse Event Reporting System (VAERS) is a national passive vaccine safety surveillance system. We analyzed US VAERS reports for MenB-FHbp received from the date of licensure in October 2014 through December 2018. We described the characteristics of the persons and adverse events (AEs) reported and calculated reporting rates using the number of doses distributed. We used empirical Bayesian data mining to identify AEs reported at least twice as often as expected compared with all other vaccines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>VAERS received 2106 reports involving MenB-FHbp, representing 698 reports per million doses distributed. The median age of vaccinees was 17 years, and 55% were female. MenB-FHbp was given simultaneously with other vaccines in 37% of reports. Most reports (57%) described AEs that started on the day of or day after vaccination. The most common AEs reported were pyrexia (27%), headache (25%), and pain (16%). There were 44 serious reports (2% of all reports), among which 42 reported a hospitalization. Data mining identified disproportional reporting of headache, pyrexia, chills, and myalgia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The AEs most commonly or disproportionately reported following MenB-FHbp were consistent with those identified in clinical trials as described in the US package insert. We did not identify any new safety issues.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaa516","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T06:40:50Z","timestamp":1603780850000},"source":"Crossref","is-referenced-by-count":10,"title":["Safety Surveillance of Bivalent Meningococcal Group B Vaccine, Vaccine Adverse Event Reporting System, 2014\u20132018"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8060-0940","authenticated-orcid":false,"given":"Jonathan","family":"Duffy","sequence":"first","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Marquez","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u00e7a M","family":"Dores","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Ng","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Su","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cano","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Perez-Vilar","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"2020122901395740000_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2020122901395740000_CIT0002","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current epidemiology and trends in meningococcal disease\u2013United States, 1996\u20132015","volume":"66","author":"MacNeil","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020122901395740000_CIT0003","author":"Wyeth Pharmaceuticals, Inc"},{"key":"2020122901395740000_CIT0004","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020122901395740000_CIT0005","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020122901395740000_CIT0006","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated recommendations for use of MenB-FHbp Serogroup B meningococcal vaccine\u2014Advisory Committee on Immunization Practices, 2016","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020122901395740000_CIT0007","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"key":"2020122901395740000_CIT0008","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/INF.0000000000001124","article-title":"A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents","volume":"35","author":"Muse","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2020122901395740000_CIT0009","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","article-title":"A bivalent meningococcal B vaccine in adolescents and young adults","volume":"377","author":"Ostergaard","year":"2017","journal-title":"N Engl J Med"},{"key":"2020122901395740000_CIT0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2020122901395740000_CIT0011","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/INF.0000000000001072","article-title":"Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine","volume":"35","author":"Senders","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2020122901395740000_CIT0012","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1097\/INF.0000000000001742","article-title":"Adverse events following vaccination with bivalent rLP2086 (Trumenba\u00ae): an observational, longitudinal study during a college outbreak and a systematic review","volume":"37","author":"Fiorito","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2020122901395740000_CIT0013","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"2020122901395740000_CIT0014"},{"key":"2020122901395740000_CIT0015","author":"Department of Health and Human Services","year":"2019"},{"key":"2020122901395740000_CIT0016","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"2020122901395740000_CIT0017","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/pds.1107","article-title":"Comparing data mining methods on the VAERS database","volume":"14","author":"Banks","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020122901395740000_CIT0018","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2008.10.006","article-title":"A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"26","author":"Gidudu","year":"2008","journal-title":"Vaccine"},{"key":"2020122901395740000_CIT0019","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"key":"2020122901395740000_CIT0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"2020122901395740000_CIT0021","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1016\/j.vaccine.2019.07.017","article-title":"Nephrotic syndrome following four-component meningococcal B vaccination: epidemiologic investigation of a surveillance signal","volume":"37","author":"De Serres","year":"2019","journal-title":"Vaccine"},{"key":"2020122901395740000_CIT0022","doi-asserted-by":"crossref","first-page":"e00393","DOI":"10.1128\/mSphere.00393-19","article-title":"Anti-Factor H antibody reactivity in young adults vaccinated with a meningococcal serogroup B vaccine containing Factor H binding protein","volume":"4","author":"Sharkey","year":"2019","journal-title":"mSphere"},{"key":"2020122901395740000_CIT0023","author":"Health Canada"},{"key":"2020122901395740000_CIT0024","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jaci.2018.12.1003","article-title":"Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990\u20132016","volume":"143","author":"Su","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2020122901395740000_CIT0025","volume-title":"Adverse Effects of Vaccines: Evidence and Causality.","author":"Stratton","year":"2011"},{"key":"2020122901395740000_CIT0026","author":"Kroger"},{"key":"2020122901395740000_CIT0027","first-page":"79","article-title":"Vaccine administration","volume-title":"Epidemiology and Prevention of Vaccine-Preventable Diseases.","author":"Centers for Disease Control and Prevention","year":"2015","edition":"13"},{"key":"2020122901395740000_CIT0028","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"2020122901395740000_CIT0029","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41433-018-0214-0","article-title":"Post-streptococcal uveitis syndrome in a Caucasian population: a case series","volume":"33","author":"Curragh","year":"2019","journal-title":"Eye (Lond)"},{"key":"2020122901395740000_CIT0030","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1016\/j.vaccine.2012.04.005","article-title":"Algorithm to assess causality after individual adverse events following immunizations","volume":"30","author":"Halsey","year":"2012","journal-title":"Vaccine"},{"key":"2020122901395740000_CIT0031","doi-asserted-by":"crossref","first-page":"e01625","DOI":"10.1128\/mBio.01625-14","article-title":"Human Factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding","volume":"5","author":"Costa","year":"2014","journal-title":"mBio"},{"key":"2020122901395740000_CIT0032","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5414\/CN107777","article-title":"The clinical spectrum of hemolytic uremic syndrome secondary to complement Factor H autoantibodies","volume":"83","author":"Kim","year":"2015","journal-title":"Clin Nephrol"},{"key":"2020122901395740000_CIT0033","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1056\/NEJMc1805857","article-title":"Factor H autoantibodies and membranous nephropathy","volume":"379","author":"Seikrit","year":"2018","journal-title":"N Engl J Med"},{"key":"2020122901395740000_CIT0034","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00467-018-3989-0","article-title":"Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"34","author":"Noris","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2020122901395740000_CIT0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pcl.2018.08.006","article-title":"Nephrotic syndrome","volume":"66","author":"Wang","year":"2019","journal-title":"Pediatr Clin North Am"},{"key":"2020122901395740000_CIT0036","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020122901395740000_CIT0037","author":"Alexion Pharmaceuticals Inc"},{"key":"2020122901395740000_CIT0038","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2015.05.006","article-title":"Vaccination errors reported to the Vaccine Adverse Event Reporting System (VAERS) United States, 2000\u20132013","volume":"33","author":"Hibbs","year":"2015","journal-title":"Vaccine"},{"key":"2020122901395740000_CIT0039","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1016\/j.vaccine.2020.09.072","article-title":"The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barre syndrome","volume":"38","author":"Miller","year":"2020","journal-title":"Vaccine"},{"key":"2020122901395740000_CIT0040","doi-asserted-by":"crossref","first-page":"718","DOI":"10.15585\/mmwr.mm6833a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2018","volume":"68","author":"Walker","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020122901395740000_CIT0041"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa516\/34037490\/ofaa516.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/12\/ofaa516\/35224930\/ofaa516.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/12\/ofaa516\/35224930\/ofaa516.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T06:40:20Z","timestamp":1609224020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa516\/5940741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa516","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,10,27]]},"article-number":"ofaa516"}}